Skip to main content

Table 1 Patient demographics and other baseline characteristics

From: Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry

 

nsNSAID (n = 219)

Celecoxib (n = 55)

Age, years, mean (SD)

8.2 (4.45)

10.0 (4.09)

Sex, n (%)

  

 Male

54 (24.7)

8 (14.5)

 Female

165 (75.3)

47 (85.5)

Race, n (%)

  

 White

193 (88.1)

49 (89.1)

 Black

16 (7.3)

5 (9.1)

 Asian

6 (2.7)

0

 Other

4 (1.8)

1 (1.8)

Ethnicity, n (%)

  

 Hispanic or Latino

19 (8.7)

2 (3.6)

 Non-Hispanic or Latino

200 (91.3)

53 (96.4)

Body mass index categories, n (%)

  

 Underweight

10 (4.6)

6 (10.9)

 Healthy weight

143 (65.3)

36 (65.5)

 Overweight

38 (17.4)

8 (14.5)

 Obese

20 (9.1)

4 (7.3)

 Missing

8 (3.7)

1 (1.8)

Months since JIA diagnosis, median (range)

4.25 (0–163.0)

12.10 (0.5–173.5)

JIA category, n (%)

  

 Systemic

3 (1.4)

0

 Persistent oligoarticular

119 (54.3)

27 (49.1)

 Extended oligoarticular

12 (5.5)

2 (3.6)

 Poly RF (–)

70 (32.0)

23 (41.8)

 Poly RF (+)

14 (6.4)

3 (5.5)

 Missing

1 (0.5)

0

Patients that have discontinued ≥1 NSAID in prior year,a n (%)

114 (52.1)

46 (83.6)

 AE

16 (7.3)

25 (45.5)

 Other reasons

64 (29.2)

15 (27.3)

 Lack of efficacy

40 (18.3)

10 (18.2)

 Both AE/lack of efficacy

3 (1.4)

4 (7.3)

Rheumatologic joint assessment, mean (SD)

  

 Number of joints with active arthritisb

2.9 (4.1)

3.4 (5.4)

 Number of joints with swelling

2.7 (4.0)

3.1 (5.1)

 Number of joints with pain on motion/tenderness

1.7 (3.6)

2.5 (4.3)

 Number of joints with loss of motion

1.7 (3.0)

1.9 (3.2)

Childhood health assessment questionnaire, median (range)

  

 Functioning (in past week)c

0.35 (0–2.5)

0.44 (0–2.5)

 Paind

0.45 (0–3.0)

0.66 (0–2.5)

 Global evaluatione

14.00 (0–87.0)

16.50 (0–97.0)

 Physician’s Global Assessment of Disease Activity,f mean (SD)

2.9 (2.2)

2.6 (2.4)

 Parent/subject assessment of overall well being,g mean (SD)

2.8 (2.5)

3.2 (2.6)

  1. aPatients discontinuing more than 1 NSAID for the same reason are only counted once in the overall summary; however, if a patient discontinued an NSAID for more than 1 reason, the patient contributes to the summary of each of those reasons.
  2. bActive arthritis is defined as swelling of the joint or, if no swelling is present, loss of motion accompanied by pain on motion or tenderness.
  3. cFunctioning can range from 0–3, where higher scores indicate more impairment.
  4. dPain can range from 0–3, where 0 = no pain and 3 = very severe pain.
  5. eGlobal evaluation can range from 0–100, where 0 = very well and 100 = very poor.
  6. fPhysician’s Global Assessment can range from 0–10, where 0 = not active and 10 = very active.
  7. gParent/subject assessment of overall well-being can range from 0–10, where 0 = very well and 10 = very poorly.
  8. Abbreviations AE: Adverse event, JIA Juvenile idiopathic arthritis, nsNSAID Nonselective nonsteroidal anti-inflammatory drug, RF Rheumatoid factor.
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096